| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C35H58N6O9 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appears to bind ubiquilins 1, 2, and 4, and it inhibits phosphorylation of eIF4E-binding protein 1 (4EBP1). It is supplied as a white to light yellow solid (C35H58N6O9, MW 706.87) at 98.63% purity.
Physical & Chemical Properties
| CAS Number | 1884710-81-9 |
|---|---|
| Molecular Formula | C35H58N6O9 |
| Molecular Weight | 706.87 g/mol |
| Purity | 98.63% |
| Appearance | Solid |
| Color | White to light yellow |
| SMILES | O=C(OC(C)(C)C)N/C(NC(OC(C)(C)C)=O)=N/CCC[C@H](NC(OC(C)(C)C)=O)C(NCCCCCCNC(OCC1=CC=CC=C1)=O)=O |
| Signaling Pathway | PI3K/Akt/mTOR |
| Solubility | In Vitro: DMSO: 20 mg/mL (28.29 mM; Requires sonication and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 20 mg/mL (28.29 mM) | requires sonication and warming; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
Cbz-B3A slows the growth of some human leukemia cell lines but is not cytotoxic. Compared with rapamycin, Cbz-B3A has a larger effect on phosphorylation of 4EBP1 than of p70S6k. Through Ubiquilins, Cbz-B3A inhibits mTOR. Cbz-B3A dose-dependently decreases the incorporation of [35S]methionine/cysteine into protein, maximal inhibition reaches 68% at 10 μM, with an EC50 of ~3 μM.
Data provided by the manufacturer.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
